» Articles » PMID: 33791873

Evidence for Human Diabetic Cardiomyopathy

Overview
Journal Acta Diabetol
Specialty Endocrinology
Date 2021 Apr 1
PMID 33791873
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Growing interest has been accumulated in the definition of worsening effects of diabetes in the cardiovascular system. This is associated with epidemiological data regarding the high incidence of heart failure (HF) in diabetic patients. To investigate the detrimental effects both of hyperglycemia and insulin resistance, a lot of preclinical models were developed. However, the evidence of pathogenic and histological alterations of the so-called diabetic cardiomyopathy (DCM) is still poorly understood in humans. Here, we provide a stringent literature analysis to investigate unique data regarding human DCM. This approach established that lipotoxic-related events might play a central role in the initiation and progression of human DCM. The major limitation in the acquisition of human data is due to the fact of heart specimen availability. Postmortem analysis revealed the end stage of the disease; thus, we need to gain knowledge on the pathogenic events from the early stages until cardiac fibrosis underlying the end-stage HF.

Citing Articles

Role of Circulating Biomarkers in Diabetic Cardiomyopathy.

Ianos R, Cozma A, Lucaciu R, Hangan A, Negrean V, Mercea D Biomedicines. 2024; 12(9).

PMID: 39335666 PMC: 11428922. DOI: 10.3390/biomedicines12092153.


"Emerging clinical approaches in diabetic cardiomyopathy: insights from clinical trials and future directions".

Moka M, K S, George M Acta Diabetol. 2024; 62(1):1-10.

PMID: 39254745 DOI: 10.1007/s00592-024-02363-5.


Role of bariatric surgery in improving diabetic cardiomyopathy: Molecular mechanisms and therapeutic perspectives (Review).

Song K, Liang D, Xiao D, Kang A, Ren Y Mol Med Rep. 2024; 30(5).

PMID: 39239741 PMC: 11411234. DOI: 10.3892/mmr.2024.13323.


A Review on the Natural Products in Treatment of Diabetic Cardiomyopathy (DCM).

Yao P, Yang X, Qiao Y Rev Cardiovasc Med. 2024; 25(5):165.

PMID: 39076497 PMC: 11267204. DOI: 10.31083/j.rcm2505165.


Diabetic Cardiomyopathy-From Basics through Diagnosis to Treatment.

Radzioch E, Dabek B, Balcerczyk-Lis M, Frak W, Fularski P, Mlynarska E Biomedicines. 2024; 12(4).

PMID: 38672121 PMC: 11048005. DOI: 10.3390/biomedicines12040765.


References
1.
Lindman B, Davila-Roman V, Mann D, McNulty S, Semigran M, Lewis G . Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study. J Am Coll Cardiol. 2014; 64(6):541-9. PMC: 4133145. DOI: 10.1016/j.jacc.2014.05.030. View

2.
Khouri S, Maly G, Suh D, Walsh T . A practical approach to the echocardiographic evaluation of diastolic function. J Am Soc Echocardiogr. 2004; 17(3):290-7. DOI: 10.1016/j.echo.2003.08.012. View

3.
Maisch B, Alter P, Pankuweit S . Diabetic cardiomyopathy--fact or fiction?. Herz. 2011; 36(2):102-15. DOI: 10.1007/s00059-011-3429-4. View

4.
RUBLER S, Dlugash J, YUCEOGLU Y, Kumral T, BRANWOOD A, GRISHMAN A . New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol. 1972; 30(6):595-602. DOI: 10.1016/0002-9149(72)90595-4. View

5.
Nyman K, Graner M, Pentikainen M, Lundbom J, Hakkarainen A, Siren R . Cardiac steatosis and left ventricular function in men with metabolic syndrome. J Cardiovasc Magn Reson. 2013; 15:103. PMC: 3842676. DOI: 10.1186/1532-429X-15-103. View